Grant: Project Grant

Natural Killer (NK) cells are pivotal in anti-tumor immunity, with promising interest in their engineering to enhance cancer cell eradication capabilities. Chimeric Antigen Receptors (CAR) represent transformative synthetic constructs, integrated into NK cells, that facilitate the specific recognition and killing of cancerous cells. Initial clinical trials have showcased CAR-NK cells as a dynamic 'living drug', capable of triggering robust anti-tumor responses in cancer patients. However, the emergence of evasive cancer cells lacking the targeted CAR antigen poses a significant challenge, undermining the efficacy of NK cell-based therapies. To address this obstacle, we propose a strategy of simultaneous targeting of multiple tumor antigens. This approach aims to circumvent antigen evasion, laying the groundwork for a more effective NK cell therapy.